Patents by Inventor Pietro Decamilli

Pietro Decamilli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7718386
    Abstract: Assays for the detection of diabetes and prediabetic status rely on exposing patient serum samples to purified ligand capable of binding autoantibodies specific for a 64kD autoantigen present on pancreatic ?-cells. The purified ligand is usually purified glutamic acid decarboxylase (GAD) or a fragment or analog thereof. Preferably, the assays will detect the presence of antibodies to both lower molecular weight GAD and higher molecular weight GAD since diabetic and prediabetic status may be associated with only one of these two forms. The assays can be performed using conventional protocols, such as radioimmunoassay, enzyme-linked immunosorbent assay, and enzyme assay. Methods for treating diabetes comprise administering pharmaceutical compositions including the purified ligand, particularly when coupled to an immunoglobulin or lymphoid cell to induce tolerance.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 18, 2010
    Assignees: The Regents of the University of California, Yale University
    Inventors: Steinunn Baekkeskov, Henk-Jan Aanstoot, Pietro Decamilli, Franco Folli, Michele Solimena
  • Publication number: 20020131963
    Abstract: Assays for the detection of diabetes and prediabetic status rely on exposing patient serum samples to purified ligand capable of binding autoantibodies specific for a 64 kD autoantigen present on pancreatic &bgr;-cells. The purified ligand is usually purified glutamic acid decarboxylase (GAD) or a fragment or analog thereof. Preferably, the assays will detect the presence of antibodies to both lower molecular weight GAD and higher molecular weight GAD since diabetic and prediabetic status may be associated with only one of these two forms. The assays can be performed using conventional protocols, such as radioimmunoassay, enzyme-linked immunosorbent assay, and enzyme assay. Methods for treating diabetes comprise administering pharmaceutical compositions including the purified ligand, particularly when coupled to an immunoglobulin or lymphoid cell to induce tolerance.
    Type: Application
    Filed: April 7, 1997
    Publication date: September 19, 2002
    Inventors: STEINUNN BAEKKESKOV, HENK-JAN AANSTOOT, PIETRO DECAMILLI, FRANCO FOLLI, MICHELE SOLIMENA
  • Patent number: 5512447
    Abstract: Assays for the detection of diabetes and prediabetic status rely on exposing patient serum samples to purified ligand capable of binding autoantibodies specific for a 64 kD autoantigen present on pancreatic .beta.-cells. The purified ligand is usually purified glutamic acid decarboxylase (GAD) or a fragment or analog thereof. Preferably, the assays will detect the presence of antibodies to both lower molecular weight GAD and higher molecular weight GAD since diabetic and prediabetic status may be associated with only one of these two forms. The assays can be performed using conventional protocols, such as radioimmunoassay, enzyme-linked immunosorbent assay, and enzyme assay. Methods for treating diabetes comprise administering pharmaceutical compositions including the purified ligand, particularly when coupled to an immunoglobulin or lymphoid cell to induce tolerance.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: April 30, 1996
    Assignees: The Regents of the University of California, Yale University
    Inventors: Steinunn Baekkeskov, Henk-Jan Aanstoot, Pietro Decamilli, Franco Folli, Michele Solimena